XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.22.1

SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended
--- | --- | --- | --- | ---
Mar. 31, 2021 | Sep. 03, 2019 | Mar. 31, 2022 | May 31, 2021 | Sep. 30, 2019 | Mar. 31, 2022 | Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  |  |  |  | $ 7,109,000 | $ 2,408,000
Mundipharma Medical Company |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Cost sharing percentage |  | 50.00% |  |  |  |  |
Mundipharma Medical Company | Affiliated Entity |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Collaborative agreement, maximum cost share |  | $ 31,200,000 |  |  |  | 31,200,000 |
Collaborative agreement, potential transaction value |  | $ 568,400,000 |  |  |  |  |
Payments related to collaborative agreement |  |  |  |  |  | 30,000,000 |
Accounts receivable, related parties |  |  | $ 100,000 |  |  | 100,000 |
Mundipharma Medical Company | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  | $ 15,500,000 |  |  | $ 15,500,000 |
Revenue, remaining performance obligation, expected timing of satisfaction, period |  |  | 1 year 9 months |  |  | 1 year 9 months |
Mundipharma Medical Company | Affiliated Entity | License of Intellectual Property |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  |  |  | $ 17,900,000 |  |
Long-term portion of deferred revenue |  |  | $ 11,100,000 |  |  | $ 11,100,000 |
Mundipharma Medical Company | Affiliated Entity | Milestone Achievement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  |  |  |  | 2,800,000 |
Mundipharma Medical Company | Affiliated Entity | Royalty |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  |  |  |  | 0 | $ 0
Janssen Pharmaceuticals, Inc. | Affiliated Entity |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Collaborative agreement, maximum cost share |  |  |  |  |  | 59,900,000 |
Payments related to collaborative agreement |  |  |  |  |  | 27,000,000 |
Election to proceed notice, period post delivery of results | 90 days |  |  |  |  |  |
Termination provisions, required period of written notice | 90 days |  |  |  |  |  |
Accounts receivable, related parties |  |  | 8,600,000 |  |  | 8,600,000 |
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  | 48,900,000 |  |  | 48,900,000 |
Janssen Pharmaceuticals, Inc. | Affiliated Entity | License of Intellectual Property |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  |  | $ 27,000,000 |  |  |
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Milestone Achievement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  | $ 3,000,000 |  |  |  |
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Royalty |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  |  |  |  | $ 0 |
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Upfront Payment |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Payments related to collaborative agreement | $ 27,000,000 |  |  |  |  |  |
Janssen Pharmaceuticals, Inc. | Affiliated Entity | R&D Funding |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Collaborative agreement, potential transaction value | 58,200,000 |  |  |  |  |  |
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Development, Regulatory, and Commercial Milestones |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Collaborative agreement, potential transaction value | $ 695,000,000 |  |  |  |  |  |

X
- Definition Collaborative Arrangement, Cost Sharing Percentage + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementCostSharingPercentage
Namespace Prefix: | cdtx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults
Namespace Prefix: | cdtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Maximum Third Party Share Of Cost + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice
Namespace Prefix: | cdtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Transaction, Potential Value + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementTransactionPotentialValue
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments Related To Collaborative Agreements + References No definition available. + Details
Name: | cdtx_PaymentsRelatedToCollaborativeAgreements
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability + References No definition available. + Details
Name: | cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition For an unclassified balance sheet, amount of receivables arising from transactions with related parties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(2)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsReceivableRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |